The U101 is a novel drug developed by TCM Biotech for the treatment of recurrent urinary tract infections (rUTI). It operates through a non-antibiotic mechanism,
creating a barrier on the inner wall of the urinary tract through oral administration. This barrier prevents pathogenic bacteria from adhering to the urothelial cells of the urinary tract.
Simultaneously, it facilitates the repair of urothelial tissue, effectively preventing recurrent urinary tract infections.
Urinary tract infections (UTIs) are the most common bacterial infections. Approximately 40-50% of healthy women have a chance of developing a UTI during their lifetime,
with 20-50% experiencing recurrent infections. The current standard therapies for preventing rUTI, according to the AUA/CUA/SUFU treatment guidelines, include:
Antibiotic therapy (strong recommendation; evidence level: Grade B)
Antibiotic prophylaxis (conditional recommendation; evidence level: Grade B)
Cranberry prophylaxis (conditional recommendation; evidence level: Grade C)
Bladder instillations of hyaluronic acid are not included in these guidelines, and instillation requires catheter insertion, making it invasive and inconvenient.
Therefore, antibiotics are almost the only choice in the clinical setting at present. However, prolonged antibiotic use raises the risk of inducing bacterial resistance.
With the successful market launch of U101 in the future, it will become a distinctive non-antibiotic oral drug for preventing recurrent urinary tract infections.
It is expected to meet the urgent needs of healthcare and provide significant medical advantages.
U101 is poised to replace low-dose antibiotics and hyaluronic acid instillations, becoming an innovative drug leading the global market for preventing recurrent urinary tract infections.
